Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)

Immunotherapy has considerably changed the treatment of lung cancer. As immunotherapy has a special mechanism of action, the disease remission that it can induce is unique. Recently, Immune Response Evaluation Criteria in Solid Tumors (iRECIST), which focus on assessing the apparent curative effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Zhang, Jingcheng, Shang, Congcong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449267/
https://www.ncbi.nlm.nih.gov/pubmed/30779329
http://dx.doi.org/10.1111/1759-7714.13010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449267/
https://www.ncbi.nlm.nih.gov/pubmed/30779329
http://dx.doi.org/10.1111/1759-7714.13010

Ejemplares similares